due to their capacity to target tumors to relieve the side effects caused by chemotherapy. Herein, a series of novel H2O2-activated theranostic prodrugs (CPTSe1-CPTSe7) were developed containing allyl phenyl selenide moieties as H2O2 acceptors. Compared with conventional boronate ester-based prodrug CPT-B, CPTSe1 was more stable in human plasma and showed a more complete release of camptothecin (CPT)
活性氧 (ROS) 反应性前药因其靶向肿瘤以减轻化疗引起的副作用的能力而受到极大关注。在此,开发了一系列包含
烯丙基苯基硒化物部分作为 H 2 O 2受体的新型 H 2 O 2激活的治疗诊断前药 ( C
PTSe1-C
PTSe7 )。与传统的基于
硼酸酯的前药C
PT-B相比,C
PTSe1在人血浆中更稳定,并且在 H 2 O 2诱导实验中表现出更完全的
喜树碱 (C
PT) 释放。C
PTSe1的选择性激活荧光信号在肿瘤细胞中的作用使其可用于实时监测 C
PT 释放和 H 2 O 2检测。此外,C
PTSe1对肿瘤细胞的选择性优于对正常细胞的选择性。我们的结果为开发 H 2 O 2响应性治疗诊断前药提供了一个新平台。